Displaying 1 - 12 of 14
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Displaying 1 - 12 of 14